Shan Dong Kexing Bioproducts 科兴制药
17 significant filings since 1 Jun 2026: 16 on equity incentive and 1 on dividend. The latest, on 8 Jul 2026: 关于2024年限制性股票激励计划第二个归属期归属结果暨股份上市的公告.
自 1 Jun 2026 起有 17 份重大公告：equity incentive 16 份、dividend 1 份。最新一份（8 Jul 2026）：关于2024年限制性股票激励计划第二个归属期归属结果暨股份上市的公告。
Price History 价格走势
250 trading days 个交易日 · High 最高 ¥41.48 · Low 最低 ¥17.06The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
No broker has changed its rating on this company in the reports held.
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 东吴证券 | 朱国广,刘若彤 | Buy 买入 | 29 Apr 2026 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 1 report. 每行为该券商近十二个月的最新研报；1 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。